Conference Call with Torrent Pharmaceuticals Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Torrent Pharmaceuticals announced Q3FY25 results Revenue at Rs 2,809 crore grew by 3% Gross Margin: 76.0%, Op. EBITDA margin at 32.5%. Op. EBITDA at Rs 914 crore, up by 5%. Net Profit after tax at Rs 503 crore, up by 14% No insulin CMO sales in the quarter. Dispatches restarted from January 2025. During the quarter, BRL depreciated by 17% YoY. Underlying revenue growth adjusted for above transient impact is 7% and Operating EBITDA growth is 12% Result PDF